ASPIRE (Breast Pain Pathway Rapid Evaluation)
Information about the ABS ASPIRE (Breast Pain Pathway Rapid Evaluation) Project
Capacity pressure on breast unit diagnostic services is recognised and to address this several units have developed specific pathways for the management of patients with isolated breast pain or mastalgia with different pathways at various stages of development, implementation and evaluation.
Consistent with a commitment to “no innovation without evaluation” ABS are running a multicentre platform study to evaluate these pathways and to deliver them. The primary outcome will be pathway safety measured by the number of breast cancers diagnosed in the 12 months following assessment. Patient satisfaction and costs of different approaches will also be assessed.
The study is now closed to new units. The first results will be available in 2026.
ASPIRE Leads
The following Leads have been appointed for the ASPIRE project:
ASPIRE Launch Webinar
The ASPIRE Launch Webinar was held on Wednesday 22nd March 2023.
ABS Breast Pain Position Statement
In February 2024 the ABS issued a updated position statement on breast pain.
ABS Breast Pain Position Statement